Key Speakers and Presentations Released for the 14th Annual RNA Therapeutics Conference
SAE Media Group reports: Ahead of the conference in February 2023, key speakers and presentations are released.
London, United Kingdom, December 14, 2022 --(PR.com)-- SAE Media Group’s 14th Annual RNA Therapeutics Conference will welcome expert speakers from big pharma companies to bring together cutting-edge discussions in the developments and challenges in the RNA Therapeutics field. The conference will take place on 8 – 9 February 2023 in London, UK – live and in person.
The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic.
RNAi continues to be a key focus of the event, in combination with RNA AI modelling and the next generation of RNA novel RNA modalities, including self-amplifying RNAs, small activating RNAs, circular RNAs and long non-coding RNAs.
The RNA therapeutics conference this year will be covering an industry outlook of the RNA therapeutic field, a review of mRNA-based therapies, advancements in AI modelling, an update on RNAi and a more in-depth review of the next generation of novel RNA modalities.
Register by 16 December to save £100 and take advantage of the early bird offer via http://www.therapeutics-rna.com/PR3prcom.
SAE Media Group have released a snapshot of the speakers and sessions that will be featured during the two-day conference, please see below:
Featured Key Conference Speakers:
• Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson
• Joseph Martinelli, Senior Director Genetic Medicine, Eli Lilly
• Ying Yu, Associated Director, AbbVie
• Martin Akerman, Chief Technical Officer, Envisagenics
• Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
• Souphalone Luangsay, Senior Principal Scientist, Roche
Key Sessions include:
AI/ML Developed RNA Therapeutics for Neurodegenerative Diseases
• Overcoming in-silico modeling challenges for neurodegenerative diseases
• How Envisagenics’ SpliceCore platform can be used in designing antisense oligonucleotides
• Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative diseases
Martin Akerman, Chief Technology Officer, Envisagenics
Genetic Medicine: State of The Art, Frontiers and Current Research
• Addressing key challenges at the forefront of the next generation of genetic medicines
• The role of Nucleic acid innovation in the development of RNA therapeutics
• Exploring delivery innovation as a crucial component in the advancement of RNA therapies
Joseph Martinelli, Executive Director, Eli Lilly
Visit the website to view the full agenda and speaker line-up at: http://www.therapeutics-rna.com/PR3prcom.
Proudly sponsored by: Abzu, eTheRNA, Roche, Sartorius BIA Separations
Exhibitors: Euroapi, PolyPeptide, Symbiosis
For sponsorship enquiries, contact Andrew Gibbons at
andrew.gibbons@saemediagroup.com or +44 (0) 20 7827 6156
For media enquiries, contact Marketing, Lamprini Balasi at
lamprini.balasi@saemediagroup.com or +44 (0) 20 7827 6732
14th Annual RNA Therapeutics
8 – 9 February 2023
London, UK
#RNATx2023
Register by 16 December 2022 and SAVE £100!
http://www.therapeutics-rna.com/PR3prcom
About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com
SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.
The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic.
RNAi continues to be a key focus of the event, in combination with RNA AI modelling and the next generation of RNA novel RNA modalities, including self-amplifying RNAs, small activating RNAs, circular RNAs and long non-coding RNAs.
The RNA therapeutics conference this year will be covering an industry outlook of the RNA therapeutic field, a review of mRNA-based therapies, advancements in AI modelling, an update on RNAi and a more in-depth review of the next generation of novel RNA modalities.
Register by 16 December to save £100 and take advantage of the early bird offer via http://www.therapeutics-rna.com/PR3prcom.
SAE Media Group have released a snapshot of the speakers and sessions that will be featured during the two-day conference, please see below:
Featured Key Conference Speakers:
• Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson
• Joseph Martinelli, Senior Director Genetic Medicine, Eli Lilly
• Ying Yu, Associated Director, AbbVie
• Martin Akerman, Chief Technical Officer, Envisagenics
• Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
• Souphalone Luangsay, Senior Principal Scientist, Roche
Key Sessions include:
AI/ML Developed RNA Therapeutics for Neurodegenerative Diseases
• Overcoming in-silico modeling challenges for neurodegenerative diseases
• How Envisagenics’ SpliceCore platform can be used in designing antisense oligonucleotides
• Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative diseases
Martin Akerman, Chief Technology Officer, Envisagenics
Genetic Medicine: State of The Art, Frontiers and Current Research
• Addressing key challenges at the forefront of the next generation of genetic medicines
• The role of Nucleic acid innovation in the development of RNA therapeutics
• Exploring delivery innovation as a crucial component in the advancement of RNA therapies
Joseph Martinelli, Executive Director, Eli Lilly
Visit the website to view the full agenda and speaker line-up at: http://www.therapeutics-rna.com/PR3prcom.
Proudly sponsored by: Abzu, eTheRNA, Roche, Sartorius BIA Separations
Exhibitors: Euroapi, PolyPeptide, Symbiosis
For sponsorship enquiries, contact Andrew Gibbons at
andrew.gibbons@saemediagroup.com or +44 (0) 20 7827 6156
For media enquiries, contact Marketing, Lamprini Balasi at
lamprini.balasi@saemediagroup.com or +44 (0) 20 7827 6732
14th Annual RNA Therapeutics
8 – 9 February 2023
London, UK
#RNATx2023
Register by 16 December 2022 and SAVE £100!
http://www.therapeutics-rna.com/PR3prcom
About SAE Media Group Conferences:
SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com
SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.
Contact
SAE Media Group
Lamprini Balasi
+44 (0) 20 7827 6732
Lamprini Balasi
+44 (0) 20 7827 6732
Contact
Categories